WallStSmart
PMN

ProMIS Neurosciences Inc.

NASDAQ: PMN · HEALTHCARE · BIOTECHNOLOGY

$10.49
-6.17% today

Updated 2026-06-05

Market cap
$91.02M
P/E ratio
P/S ratio
4,016.22x
EPS (TTM)
$-18.60
Dividend yield
52W range
$6 – $40
Volume
0.0M

ProMIS Neurosciences Inc. (PMN) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20052006200720082009201020112012201320152016201720182019202020212022202320242025
Revenue$31314.00$219921.00$464019.00$193631.00$1.10M$1.23M$49516.00$48666.00$344541.00$19935.00$2002.00$7868.00$348.00$1202.00$1565.00$8138.00$8138.00$0.00$0.00$0.00
Revenue growth (YoY)+602.3%+111.0%-58.3%+466.5%+12.2%-96.0%-1.7%+608.0%-94.2%-90.0%+293.0%-95.6%+245.4%+30.2%+420.0%+0.0%-100.0%
Cost of revenue$1.06M$4.74M$3.18M$5.85M$15070.00$10.44M
Gross profit$31314.00$219921.00$464019.00$193631.00$176161.00$1.23M$91090.00$48666.00$134181.00$-1.04M$2002.00$7868.00$348.00$-4.73M$-3.18M$-5.84M$-15070.00$-10.44M
Gross margin100.0%100.0%100.0%100.0%16.1%100.0%184.0%100.0%38.9%-5218.0%100.0%100.0%100.0%-393853.2%-203296.1%-71803.0%-185.2%
R&D$944197.00$2.95M$6.06M$3.27M$3.62M$3.25M$2.04M$1.77M$1.27M$763961.00$1.39M$3.15M$5.44M$4.74M$3.18M$4.95M$21.62M$7.88M$10.64M$33.38M
SG&A$608.00$484442.00$476133.00$898064.00$682259.00$1.17M$1.64M$2.02M$2.62M$2.44M$3.31M$9.80M$7.39M$6.19M$6.79M
Operating income$-1.27M$-7.58M$-5.95M$-4.63M$-3.33M$-2546.00$-2.23M$-2.04M$-2.04M$-2.10M$-2.56M$-4.78M$-7.46M$-12.13M$-5.66M$-8.25M$-31.41M$-18.90M$-16.83M$-40.17M
Operating margin-4069.8%-3445.6%-1283.1%-2388.9%-303.4%-0.2%-4510.1%-4188.8%-591.7%-10519.0%-127804.9%-60772.8%-2145008.6%-1009282.5%-361814.2%-101372.2%-386019.3%
EBITDA$-1.26M$-7.41M$-3.90M$-4.48M$-3.13M$-2.49M$-2.30M$-2.02M$-2.88M$-1.51M$-2.55M$-4.78M$-7.46M$-7.39M$-5.65M$-9.33M$-23.88M$-17.81M$2.86M$-39.72M
EBITDA margin-4038.1%-3370.0%-840.2%-2313.6%-285.1%-202.1%-4650.2%-4158.4%-835.8%-7552.6%-127556.9%-60705.4%-2143600.9%-614617.2%-360823.4%-114622.7%-293378.8%
EBIT$-1.27M$-7.58M$-4.06M$-4.63M$-3.34M$-2.56M$-2.35M$-2.04M$-2.89M$-1.51M$-2.56M$-4.78M$-7.46M$-7.40M$-5.66M$-9.37M$-23.89M$-17.84M$2.70B
Interest expense$1610.00$3.67M$6.99M$193631.00$131511.00$46985.00$13530.00$2286.00$23982.00$15888.00$5648.00$0.00$0.00$0.00$416286.00$378993.00$201390.00$76775.00$0.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-1.65M$-7.11M$-5.68M$-4.50M$-3.05M$-2.55M$-2.26M$-2.04M$-2.04M$-1.53M$-2.57M$-4.79M$-7.46M$-7.40M$-5.66M$-11.98M$-24.27M$-17.51M$2.78M$-39.72M
Net income growth (YoY)-331.4%+20.0%+20.8%+32.2%+16.4%+11.2%+10.0%+0.0%+25.0%-68.2%-86.2%-55.9%+0.9%+23.4%-111.6%-102.6%+27.9%+115.9%-1529.3%
Profit margin-5260.2%-3231.0%-1224.9%-2324.8%-278.2%-207.2%-4573.2%-4188.8%-591.7%-7666.9%-128395.3%-60844.6%-2145008.6%-615329.4%-361814.2%-147204.1%-298221.1%

Frequently asked questions

What is ProMIS Neurosciences Inc.'s revenue?

ProMIS Neurosciences Inc.'s trailing twelve-month revenue is $7560.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does PMN generate?

PMN produced $-28.12M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is PMN's balance sheet healthy?

PMN holds $6.12M in cash and equivalents against — in long-term debt, on $-1.26M of shareholder equity. That debt is best read against the cash flow the business throws off each year.